Skip to main content

CD19 CAR-T Relapse: 7 of 50 in Erlangen, Rescued With BCMA

hhhdalmolin@gmail.com
Nov 18, 2026 6:24 am

Relapse after CD19 CAR-T was rare in lupus and common in anti-synthetase syndrome and Scl-70 scleroderma. Six of seven relapsing patients were treated with BCMA-directed therapy and responded again.

CD19 CAR T-cell therapy can induce drug-free remission in refractory SLE, systemic sclerosis (SSc) and idiopathic inflammatory myopathy (IIM). The open question is durability. Andreas Wirsching, Georg Schett and colleagues (Erlangen) followed all 50 adults treated between March 2021 and July 2025, each for at least 6 months (Abstract 2632).

Seven (14%) relapsed, at a median of 18 months (range 9 to 25). By disease, that was 1/28 in SLE, 3/14 in SSc and 3/8 in IIM. Serology tracked the risk. All three IIM relapses were anti-synthetase syndrome (ASyS), two Jo-1 and one PL-7. All three SSc relapses were Scl-70 positive and came late, with progression in skin and lung and, in two patients, the heart. The single SLE relapse was dsDNA positive and came at 9 months with new transverse myelitis.

Both Jo-1 patients and the SLE patient received idecabtagene vicleucel, one of them within CARAMBA, Erlangen's phase I/II trial of BCMA CAR-T in autoimmune disease resistant to B-cell depletion. One Jo-1 patient had first responded only briefly to daratumumab and is now in drug-free remission. The SLE patient reached DORIS remission, with anifrolumab added for residual interface dermatitis. Two SSc patients received teclistamab, a BCMA x CD3 T-cell engager, and the third entered CARAMBA. The PL-7 patient improved on obinutuzumab plus nintedanib. All three IIM patients reached an ACR moderate or major response. For SSc, the abstract reports success without skin scores or lung function.

The pattern fits what CD19 targeting leaves behind. Long-lived plasma cells are largely CD19 negative and express BCMA. ASyS and Scl-70 SSc may lean more on that compartment than dsDNA-positive lupus. The abstract has no plasma cell or autoantibody data at relapse to test it.

The numbers are small and follow-up differs by disease. Even so, one relapse in 28 lupus patients is a solid durability signal. In ASyS and Scl-70 SSc, relapse should be expected: follow these patients past 2 years and have a BCMA option ready. The next data to watch are CARAMBA results and whether these serotypes should start with BCMA or dual CD19/BCMA targeting.

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×